Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer

This study has been withdrawn prior to enrollment.
(Lack of accrual)
Sponsor:
Collaborators:
Novartis
Board of Regents, State of Louisiana
Information provided by (Responsible Party):
Bridgette Collins-Burow, Tulane University
ClinicalTrials.gov Identifier:
NCT00993642
First received: October 9, 2009
Last updated: March 9, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Study Completion Date: December 2010
  Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)